The Nuka Way

Steven R. Peskin, MD, MBA, FACP

One of the four 2011 Malcolm Baldridge National Quality Award winners in health care is Southcentral Foundation, a nonprofit organization established in 1982 to serve Alaska Natives who live in and around Anchorage. The Southcentral Foundation (SCF) describes itself as a Nuka system of care — Nuka being an Alaska native name given to strong, honorable structures or living things. The four guiding principles of the Southcentral Foundation are that it be customer-driven, that customers (patients) should know and trust the health care team, that customers should face no barriers to access care, and that employees are vital to system success. SCF has achieved the highest level of recognition of Patient-Centered Medical Home from NCQA.

The system has achieved remarkable results that include clinical improvement in patients with chronic conditions, notably diabetes, which is experienced in the native population at twice national rates; wellness and preventive services; emotional and social health; and dental care. These remarkable quality results have occurred with concurrent reductions in services: Emergency room and urgent care visits are 50% lower, hospital admissions decreased 53%, specialty care declined 65% and even primary care visits decreased 36%.

I believe clinical, operational, and service performance are central to SCF’s outstanding performance. One characteristic is the attainment of trust. The erosion of trust in our health care system and the profound negative consequences that erode quality and drive up costs are well described in David Shore’s book, The Trust Crisis in Healthcare.

Another characteristic is team-based care. Southcentral Foundation very effectively uses a wide range of clinicians and other staff to meet the needs of customers (patients). And finally, it is a learning organization undergirded by an information system that allows for real-time assessment of clinical, operational, and service performance

Though Alaska is geographically, culturally, and demographically distinct from the lower 48, the performance achieved by Southcentral Foundation there should translate to other communities.

Steven R. Peskin, MD, MBA, FACP, is medical director of Horizon Healthcare Innovations, Horizon Blue Cross Blue Shield of New Jersey, and associate clinical professor of medicine at the University of Medicine and Dentistry of New Jersey — Robert Wood Johnson Medical School.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.